{"disease":{"id":"als","name":"als"},"drugs":{"marketed":[{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a third dose administered at least 2 months after either the second dose of a 2-dose series or the first dose of a single-dose regimen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a fourth dose administered at least 2 months after the third dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"abrysvo","indication_name":"Prevention of rabies in individuals who have been bitten or otherwise exposed to rabies or have been at risk of rabies exposure and have been vaccinated with a cell culture vaccine or an inactivated rabies vaccine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrysvo","generic_name":"abrysvo","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"RSV","drug_class":"vaccine","quality_score":60,"revenue":"1033","mechanism":"ABRYSVO is a vaccine that protects against respiratory syncytial virus (RSV)."},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose and an eleventh dose administered at least 2 months after the tenth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose and an eleventh dose administered at least 2 months after the tenth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose and an eleventh dose administered at least 2 months after the tenth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose and an eleventh dose administered at least 2 months after the tenth dose and a twelfth dose administered at least 2 months after the eleventh dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tozinameran-5-to-11-years-of-age","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tozinameran 5 to 11 Years of age","generic_name":"tozinameran-5-to-11-years-of-age","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with certain immunocompromised individuals","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with certain immunocompromised individuals","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with certain immunocompromised individuals","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"famtozinameran-5-to-11-years-of-age","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Famtozinameran 5 to 11 Years of age","generic_name":"famtozinameran-5-to-11-years-of-age","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"Monoclonal antibody","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"tozinameran-6-months-to-4-years-of-age","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tozinameran 6 months to 4 years of age","generic_name":"tozinameran-6-months-to-4-years-of-age","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-bivalent-wt-omi-ba-1","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 Bivalent (WT/OMI BA.1)","generic_name":"bnt162b2-bivalent-wt-omi-ba-1","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-bivalent-wt-omi-ba-1","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 Bivalent (WT/OMI BA.1)","generic_name":"bnt162b2-bivalent-wt-omi-ba-1","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-bivalent-wt-omi-ba-1","indication_name":"Prevention of COVID-19 in individuals 6 months through 4 years of age","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 Bivalent (WT/OMI BA.1)","generic_name":"bnt162b2-bivalent-wt-omi-ba-1","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"combination-bivalent-bnt162b2-and-bnt162b2-omi","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Combination (Bivalent) BNT162b2 and BNT162b2 OMI","generic_name":"combination-bivalent-bnt162b2-and-bnt162b2-omi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"combination-bivalent-bnt162b2-and-bnt162b2-omi","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Combination (Bivalent) BNT162b2 and BNT162b2 OMI","generic_name":"combination-bivalent-bnt162b2-and-bnt162b2-omi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Tetanus, diphtheria, and pertussis toxoids adsorbed (Tdap) booster dose in individuals 11 through 64 years of age","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Catch-up vaccination for individuals 13 through 18 years of age who have not previously completed the series","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Routine vaccination of individuals 11 through 64 years of age with certain risk factors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"riltozinameran-12-years-of-age-and-older","indication_name":"Amyotrophic lateral sclerosis (ALS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riltozinameran 12 Years of age and older","generic_name":"riltozinameran-12-years-of-age-and-older","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":34,"revenue":null,"mechanism":"Mechanism of action is not specified on Wikipedia."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"bnt162b7-bivalent-original-omi-ba-4-ba-5","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b7 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b7-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":55,"revenue":null,"mechanism":"BNT162b7 Bivalent is a mRNA-based vaccine targeting SARS-CoV-2 spike protein."},{"drug_id":"bnt162b7-bivalent-original-omi-ba-4-ba-5","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b7 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b7-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":55,"revenue":null,"mechanism":"BNT162b7 Bivalent is a mRNA-based vaccine targeting SARS-CoV-2 spike protein."},{"drug_id":"bnt162b2-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BNT162b2 vaccine","company_name":"Vaxxinity, Inc.","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified"},{"drug_id":"bnt162b2-vaccine","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BNT162b2 vaccine","company_name":"Vaxxinity, Inc.","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified"},{"drug_id":"bnt162b2-vaccine","indication_name":"Prevention of COVID-19 in individuals 6 months through 4 years of age","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BNT162b2 vaccine","company_name":"Vaxxinity, Inc.","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified"},{"drug_id":"investigational-covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Investigational COVID-19 Vaccine","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"investigational-covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 6 months through 4 years of age","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Investigational COVID-19 Vaccine","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"investigational-covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Investigational COVID-19 Vaccine","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"investigational-covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 6 months through 4 years of age with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Investigational COVID-19 Vaccine","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"investigational-covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Investigational COVID-19 Vaccine","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"investigational-covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Investigational COVID-19 Vaccine","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)","generic_name":"tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1","indication_name":"Prevention of COVID-19 in individuals 6 months through 4 years of age","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)","generic_name":"tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)","generic_name":"tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older as a booster dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)","generic_name":"tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older as a booster dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)","generic_name":"tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1","indication_name":"Prevention of COVID-19 in individuals 6 months through 4 years of age as a booster dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)","generic_name":"tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"neurontin","indication_name":"Seizures associated with amyotrophic lateral sclerosis (ALS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neurontin","generic_name":"Gabapentin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"α2δ subunit of voltage-activated calcium channels","drug_class":"Antiepileptic/Analgesic","quality_score":10,"revenue":null,"mechanism":"Gabapentin binds with high-affinity to α2δ subunit of voltage-activated calcium channels; precise mechanism unknown."},{"drug_id":"incobotulinumtoxina","indication_name":"Spasticity caused by cerebral palsy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"bnt162b2-omi-kp-2","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi KP.2)","generic_name":"bnt162b2-omi-kp-2","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-kp-2","indication_name":"Prevention of COVID-19 in individuals 6 months through 4 years of age","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi KP.2)","generic_name":"bnt162b2-omi-kp-2","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-kp-2","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi KP.2)","generic_name":"bnt162b2-omi-kp-2","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-kp-2","indication_name":"Prevention of COVID-19 in individuals 6 months through 4 years of age with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi KP.2)","generic_name":"bnt162b2-omi-kp-2","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-kp-2","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi KP.2)","generic_name":"bnt162b2-omi-kp-2","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-kp-2","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi KP.2)","generic_name":"bnt162b2-omi-kp-2","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"incobotulinumtoxina","indication_name":"Upper limb spasticity in pediatric patients (excluding cerebral palsy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"bnt162b5-bivalent-wt-omi-ba-2","indication_name":"COVID-19 prevention in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b5 Bivalent (WT/OMI BA.2)","generic_name":"bnt162b5-bivalent-wt-omi-ba-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b5-bivalent-wt-omi-ba-2","indication_name":"COVID-19 treatment in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b5 Bivalent (WT/OMI BA.2)","generic_name":"bnt162b5-bivalent-wt-omi-ba-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-ba-4-5-bivalent","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 BA.4/5 bivalent","generic_name":"bnt162b2-ba-4-5-bivalent","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-ba-4-5-bivalent","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 BA.4/5 bivalent","generic_name":"bnt162b2-ba-4-5-bivalent","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-ba-4-5-bivalent","indication_name":"Prevention of COVID-19 in individuals 6 months through 4 years of age","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 BA.4/5 bivalent","generic_name":"bnt162b2-ba-4-5-bivalent","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)","generic_name":"bnt162b2-omi-xbb-1-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a third dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a third dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a third dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a fourth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a fourth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a fourth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a fifth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a fifth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a fifth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a sixth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a sixth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a sixth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a seventh dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a seventh dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a seventh dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as an eighth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as an eighth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as an eighth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine, and when administered to individuals who have completed primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine, and when administered to individuals who have completed primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine, and when administered to individuals who have completed primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older who have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-10-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-10-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-10-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 6 months through 11 years of age","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-10-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)","generic_name":"bnt162b2-omi-xbb-1-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)","generic_name":"bnt162b2-omi-xbb-1-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)","generic_name":"bnt162b2-omi-xbb-1-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)","generic_name":"bnt162b2-omi-xbb-1-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)","generic_name":"bnt162b2-omi-xbb-1-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)","generic_name":"bnt162b2-omi-xbb-1-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)","generic_name":"bnt162b2-omi-xbb-1-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)","generic_name":"bnt162b2-omi-xbb-1-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)","generic_name":"bnt162b2-omi-xbb-1-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"bnt162b2-bivalent-original-omicron-ba-4-ba-5-30-mcg","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg","generic_name":"bnt162b2-bivalent-original-omicron-ba-4-ba-5-30-mcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Spike protein","drug_class":"mRNA vaccine","quality_score":55,"revenue":null,"mechanism":"Stimulates the body's immune system to produce antibodies against the SARS-CoV-2 virus."},{"drug_id":"bnt162b2-bivalent-original-omicron-ba-4-ba-5-30-mcg","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg","generic_name":"bnt162b2-bivalent-original-omicron-ba-4-ba-5-30-mcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Spike protein","drug_class":"mRNA vaccine","quality_score":55,"revenue":null,"mechanism":"Stimulates the body's immune system to produce antibodies against the SARS-CoV-2 virus."},{"drug_id":"bnt162b2-bivalent-original-omicron-ba-4-ba-5-30-mcg","indication_name":"Prevention of COVID-19 in individuals 6 months through 4 years of age","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg","generic_name":"bnt162b2-bivalent-original-omicron-ba-4-ba-5-30-mcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Spike protein","drug_class":"mRNA vaccine","quality_score":55,"revenue":null,"mechanism":"Stimulates the body's immune system to produce antibodies against the SARS-CoV-2 virus."},{"drug_id":"undecanoate","indication_name":"Toxic damage from alcohol or heavy metals","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tlando","generic_name":"UNDECANOATE","company_name":"Tolmar","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Tlando works by increasing testosterone levels in the body."},{"drug_id":"licensed-influenza-vaccine-3","indication_name":"Intranasal influenza vaccine for active immunization against influenza disease caused by influenza virus types A and B, in individuals 6 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Assorted Licensed Hand Sanitizer Grape 01","generic_name":"Licensed Influenza Vaccine 3","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Influenza virus hemagglutinin protein","drug_class":"Vaccine","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Covid-19 Sterilizing","generic_name":"COVID-19 Vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older for the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Covid-19 Sterilizing","generic_name":"COVID-19 Vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older for the Moderna COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Covid-19 Sterilizing","generic_name":"COVID-19 Vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older for the Novavax COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Covid-19 Sterilizing","generic_name":"COVID-19 Vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older for the Janssen COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Covid-19 Sterilizing","generic_name":"COVID-19 Vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"tozinameran-12-years-of-age-and-older","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tozinameran 12 Years of age and older","generic_name":"tozinameran-12-years-of-age-and-older","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"bnt162b7-monovalent-omi-ba-4-ba-5","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b7 Monovalent (OMI BA.4/BA.5)","generic_name":"bnt162b7-monovalent-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"cromolyn-sodium","indication_name":"Amyotrophic Lateral Sclerosis (ALS)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CROMOLYN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"Mast cells","drug_class":"Mast cell stabilizer","quality_score":30,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":412,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT07433777","title":"Reference Intervals With Indirect Methods in Italy","phase":"","overall_status":"RECRUITING","enrollment_count":1000000,"lead_sponsor_name":"Centro di Riferimento Oncologico - Aviano","has_results":false},{"nct_id":"NCT03413566","title":"Trends in Prevalence and Comorbidities of Children With Cerebral Palsy in Norway","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":707916,"lead_sponsor_name":"Sykehuset i Vestfold HF","has_results":false},{"nct_id":"NCT04688372","title":"Hospital COVID-19 Surge and Associated Mortality Risk","phase":"","overall_status":"COMPLETED","enrollment_count":144116,"lead_sponsor_name":"National Institutes of Health Clinical Center (CC)","has_results":false},{"nct_id":"NCT04360564","title":"RPL: Interval to Live Birth and Adverse Perinatal Outcomes","phase":"","overall_status":"UNKNOWN","enrollment_count":140000,"lead_sponsor_name":"Children's & Women's Health Centre of British Columbia","has_results":false},{"nct_id":"NCT06209515","title":"Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61292,"lead_sponsor_name":"Kuopio University Hospital","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT03667079","title":"Integrating Community Interventions to Eliminate Neglected Tropical Diseases","phase":"NA","overall_status":"COMPLETED","enrollment_count":28143,"lead_sponsor_name":"Washington State University","has_results":false},{"nct_id":"NCT06633393","title":"Effect of a Myopia Prediction System on Myopia Prevention and Control","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Zhongshan Ophthalmic Center, Sun Yat-sen University","has_results":false},{"nct_id":"NCT03047369","title":"The Myelin Disorders Biorepository Project","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT06203106","title":"NYSCF Scientific Discovery Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT06453616","title":"Evaluating the Effectiveness of the \"Hello Bundle\" Intervention in Reducing Burnout Among ICU Healthcare Professionals","phase":"NA","overall_status":"COMPLETED","enrollment_count":7300,"lead_sponsor_name":"Saint-Louis Hospital, Paris, France","has_results":false},{"nct_id":"NCT04001166","title":"Pharmacogenomics of Antithrombotic Drugs -a Register Linkage Study With National Registries and Biobanks in Finland","phase":"","overall_status":"COMPLETED","enrollment_count":7005,"lead_sponsor_name":"VTT Technical Research Centre of Finland","has_results":false},{"nct_id":"NCT05966038","title":"ALS/MND Natural History Study Data Repository","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT06583395","title":"Quest to Analyze One Thousand Humans Meditating","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3000,"lead_sponsor_name":"Tobias Moeller-Bertram","has_results":false},{"nct_id":"NCT04603144","title":"Identification of Frailty Predictors of Adverse Health Outcomes in Community-dwelling Individuals Aged 50 and Over","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03402022","title":"Drug Use and Ultra-endurance Race","phase":"","overall_status":"COMPLETED","enrollment_count":2923,"lead_sponsor_name":"University Hospital, Grenoble","has_results":false},{"nct_id":"NCT03924414","title":"Trial of Parkinson's And Zoledronic Acid","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2650,"lead_sponsor_name":"California Pacific Medical Center Research Institute","has_results":false},{"nct_id":"NCT03464279","title":"Use of a Behavioral Economic Intervention to Reduce Antibiotic Prescription for Upper Respiratory Infections","phase":"NA","overall_status":"COMPLETED","enrollment_count":2500,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT06205433","title":"Evaluating the Impact of Training for IHSS Workers","phase":"NA","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Abdul Latif Jameel Poverty Action Lab","has_results":false},{"nct_id":"NCT06857071","title":"Expanded Social Network Recruitment to HIV Testing (E-SNRHT) Intervention to Locate Undiagnosed Cases and Reduce HIV-related Stigma","phase":"NA","overall_status":"RECRUITING","enrollment_count":2480,"lead_sponsor_name":"University of Illinois at Chicago","has_results":false},{"nct_id":"NCT06198777","title":"Determination of MCG Reference Intervals in Healthy Individuals","phase":"","overall_status":"UNKNOWN","enrollment_count":2396,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT04363684","title":"ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)","phase":"","overall_status":"RECRUITING","enrollment_count":2100,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06885918","title":"ALS Research Collaborative","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"ALS Therapy Development Institute","has_results":false},{"nct_id":"NCT03233646","title":"Retinal Imaging in Neurodegenerative Disease","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT06537622","title":"Best Practices Fo Early Diagnosis of Cerebral Palsy","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"St. Justine's Hospital","has_results":false},{"nct_id":"NCT06949865","title":"AI-Enhanced Optimization of Acute Levodopa Challenge Test","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT06848959","title":"Development and Application of a Diagnosis and Treatment System for Children's Brain Diseases Based on Knowledge Graphs and Large Models","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Yun Liu,PhD","has_results":false},{"nct_id":"NCT05006001","title":"Evaluation of Colchicine and Nonsteroidal Anti-inflammatory Drug Combination Therapy and Renal Function in Gout Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"En Chu Kong Hospital","has_results":false},{"nct_id":"NCT02918435","title":"Implementing an Intervention to Address Social Determinants of Health in Pediatric Practices","phase":"NA","overall_status":"COMPLETED","enrollment_count":1872,"lead_sponsor_name":"University of Massachusetts, Worcester","has_results":false},{"nct_id":"NCT01530165","title":"(Pakistan Diabetes Prevention Program PDPP)","phase":"NA","overall_status":"COMPLETED","enrollment_count":1564,"lead_sponsor_name":"Aga Khan University","has_results":false},{"nct_id":"NCT05262088","title":"Prognostic Value of Generalized Movements in the Diagnosis of Neurological Diseases in Children","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"West Kazakhstan Medical University","has_results":false},{"nct_id":"NCT05907837","title":"Early Detection & Intervention of Cerebral Palsy in Ireland","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"University College Cork","has_results":false},{"nct_id":"NCT04735744","title":"Evaluation of Allied Healthcare in Patients Recovering From COVID-19","phase":"","overall_status":"UNKNOWN","enrollment_count":1441,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT06112912","title":"Components Study of REAL Essentials","phase":"","overall_status":"COMPLETED","enrollment_count":1301,"lead_sponsor_name":"Mathematica Policy Research, Inc.","has_results":false},{"nct_id":"NCT04270604","title":"Biological Sample Collection for Research and Biobanking","phase":"","overall_status":"TERMINATED","enrollment_count":1279,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT07235111","title":"Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Ospedale Policlinico San Martino","has_results":false},{"nct_id":"NCT05402033","title":"Cancer Clinical Trials Financial Reimbursement Program","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT06002113","title":"Eliciting Informed Goals of Care in Elderly Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Royal Victoria Hospital, Canada","has_results":false},{"nct_id":"NCT04509544","title":"Satisfaction and Preferences About Motor Rehabilitation in People With Cerebral Palsy: ESPaCe, a French Survey","phase":"","overall_status":"COMPLETED","enrollment_count":1159,"lead_sponsor_name":"Fondation Paralysie Cérébrale","has_results":false},{"nct_id":"NCT04792606","title":"Long-Term Outcomes of Hip Interventions for Children With Cerebral Palsy","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"The Hospital for Sick Children","has_results":false},{"nct_id":"NCT04031469","title":"A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease","phase":"","overall_status":"SUSPENDED","enrollment_count":1000,"lead_sponsor_name":"ProgenaBiome","has_results":false},{"nct_id":"NCT06575283","title":"Predicting Cerebral Palsy in Infants With White Matter Injury Using MRI","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT04715399","title":"UPenn Observational Research Repository on Neurodegenerative Disease","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT07189494","title":"European Newborn Study: Early Markers for a Better LifE","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"dr. M.J.N.L. Benders","has_results":false},{"nct_id":"NCT06377033","title":"Using the EHR to Advance Genomic Medicine Across a Diverse Health System","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT05026645","title":"The Medical Management in Patients Exposed to Weapons of Mass Destruction","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1000,"lead_sponsor_name":"St. Justine's Hospital","has_results":false},{"nct_id":"NCT07233148","title":"Healing ALS Registry Observational Study (HAROS)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Healing Advocates Registry and Ministry","has_results":false},{"nct_id":"NCT06647641","title":"The CurePSP Genetics Program","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT03452956","title":"Cognitive Impairement In Frontotemporal Dementia","phase":"","overall_status":"COMPLETED","enrollment_count":997,"lead_sponsor_name":"University of Pennsylvania","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}